A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Oral Doses Of PF-03654764 In Healthy Subjects.

Trial Profile

A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Oral Doses Of PF-03654764 In Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2009

At a glance

  • Drugs PF 3654764 (Primary)
  • Indications Cognition disorders
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Oct 2009 Additional locations (Singapore) added as reported by ClinicalTrials.gov.
    • 28 Oct 2009 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top